Loading…
Underlying
Underlying Price
$6.01
Type
Call
Strike
15
Expiration
Dec 11, 2026
DTE
28d
Moneyness
OTM
Intrinsic
$0.00
IBRX 15 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Nov 13, 2026 | 0d | — | — | 0 | 0 |
| Nov 20, 2026 | 7d | $0.05 | -50.00% | 7 | 1,323 |
| Nov 27, 2026 | 14d | $0.35 | +0.00% | 41 | 41 |
| Dec 4, 2026 | 21d | — | — | 0 | 0 |
| Dec 11, 2026 | 28d | — | — | 0 | 0 |
| Dec 18, 2026 | 35d | — | — | 0 | 0 |
| Dec 24, 2026 | 41d | — | — | 0 | 0 |
| Jan 15, 2027 | 63d | $0.28 | -30.00% | 320 | 12,449 |
| Mar 19, 2027 | 126d | $0.40 | -20.00% | 3 | 2,113 |
| Apr 16, 2027 | 154d | $0.75 | -6.25% | 2 | 75 |
| May 21, 2027 | 189d | $2.00 | +14.29% | 115 | 1,178 |
| Aug 20, 2027 | 280d | $1.42 | -16.96% | 4 | 42 |
| Nov 19, 2027 | 371d | $3.78 | +122.35% | 1 | 9 |
| Jan 21, 2028 | 434d | $1.85 | +8.82% | 44 | 7,504 |
| Mar 17, 2028 | 490d | $2.04 | +10.27% | 8 | 249 |
| Jan 19, 2029 | 798d | $2.80 | -5.08% | 3 | 400 |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.